Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I

T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK) with a specific conversion protocol for the T cells from the patient, to perform anti-cancer therapy, especially for those cancers that are lack of MHC-I molecule expression. We have finished pre-clinical investigations for the ITNK or CAR-ITNK cell therapy and scheduled to start a clinical phase I study.

NCT Number	NCT03882840
Lead Sponsor	Second Affiliated Hospital of Guangzhou Medical University Collaborators: Hunan Zhaotai Yongren Medical Innovation Co. Ltd.
Conditions	Anti-cancer Cell Immunotherapy, T Cell and NK Cell
Enrollment	60 participants
Start Date	2019-01-01
Primary Completion	2028-01-01 (estimated)
Study Completion	2035-01-01 (estimated)
Updated on ClinicalTrials.gov	2024-06-26